We’ve updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.
How has the budesonide inhaler grown historically, and what trends indicate future expansion?
The budesonide inhaler market size has grown strongly in recent years. It will grow from $6.37 billion in 2024 to $6.94 billion in 2025 at a compound annual growth rate (CAGR) of 9.0%. The growth in the historic period can be attributed to rising awareness regarding inhalation therapies, increasing adoption of corticosteroid treatments, rise in air pollution levels contributing to respiratory issues, increasing demand for minimally invasive drug delivery, and increasing focus on home healthcare solutions.
The budesonide inhaler market size is expected to see strong growth in the next few years. It will grow to $9.68 billion in 2029 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to increasing investment in respiratory drug development, rising demand for personalized medicine in respiratory care, rising use of telemedicine and e-prescriptions, increasing awareness of early diagnosis and treatment, and rising preference for combination inhaler therapies. Major trends in the forecast period include advanced formulation techniques for enhanced drug delivery, innovation in smart inhalers with digital tracking, integration of AI and IoT in respiratory health management, advancement in patient-centric drug designs, and integration of mobile apps for adherence monitoring.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24181&type=smp
Which key factors are driving the expansion of the budesonide inhaler industry?
The rising prevalence of respiratory disorders is expected to propel the growth of the budesonide inhaler market going forward. Respiratory disorders are medical conditions that affect the lungs and airways, making breathing difficult and often causing symptoms such as coughing, wheezing, and shortness of breath. It includes asthma, chronic obstructive pulmonary disease (COPD), pneumonia, bronchitis, and lung infections. The rise in respiratory disorders is mainly due to rising air pollution, which increases the exposure to harmful pollutants that irritate the airways and worsen lung function. Budesonide inhalers manage respiratory disorders by delivering anti-inflammatory medication directly to the lungs, offering long-term control. Their compact design makes them easy to use and carry, reducing flare-ups and improving respiratory health. For instance, in December 2023, according to the Australian Bureau of Statistics, an Australia-based government agency, the prevalence of chronic obstructive pulmonary disease (COPD) rose from 2.4% in 2021 to 2.5% in 2022. Therefore, the rising prevalence of respiratory disorders is driving the growth of the budesonide inhaler market.
How is the budesonide inhaler market segmented by product, application, and end-user?
The budesonide inhaler market covered in this report is segmented –
1) By Product Type: Metered-Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs), Nebulizers, Combination Inhalers
2) By Dosage Form: Aerosols, Dry Powder, Suspension, Spray
3) By Indication: Asthma, Chronic Obstructive Pulmonary Disease, Allergic Rhinitis
4) By End User: Hospitals, Outpatient Clinics, Homecare Settings, Pharmacies
Subsegments:
1) Metered-Dose Inhalers: Pressurized Metered-Dose Inhalers, Breath-Actuated Metered-Dose Inhalers, Spacer-Compatible Metered-Dose Inhalers, Hydrofluoroalkane Propellant-Based Metered-Dose Inhalers
2) Dry Powder Inhalers: Single-Dose Dry Powder Inhalers, Multi-Dose Dry Powder Inhalers, Capsule-Based Dry Powder Inhalers, Reservoir-Based Dry Powder Inhalers
3) Nebulizers: Jet Nebulizers, Ultrasonic Nebulizers, Mesh Nebulizers, Homecare Nebulizers, Hospital-Use Nebulizers
4) Combination Inhalers: Budesonide And Formoterol Inhalers, Budesonide And Salmeterol Inhalers, Budesonide, Glycopyrrolate, And Formoterol Inhalers, Budesonide And Vilanterol Inhalers
View The Full Market Report:
https://www.thebusinessresearchcompany.com/report/budesonide-inhaler-global-market-report
Which major trends are influencing the growth of the budesonide inhaler industry?
Major companies operating in the budesonide inhaler market are focusing on developing innovative products, such as generic products, to improve affordability and ensure wider access to treatment for respiratory conditions. Generic inhalation products refer to non-branded versions of inhaled medications that deliver the same active ingredients, dosage, and therapeutic effects as their branded counterparts, typically at a lower cost. For instance, in July 2023, Viatris Inc., a US-based pharmaceutical company, in collaboration with Kindeva Drug Delivery L.P., a US-based pharmaceutical manufacturing company, launched Breyna (budesonide and formoterol fumarate dihydrate) inhalation aerosol, the first Food and Drug Administration (FDA), a US-based federal agency-approved generic version of Symbicort. This drug-device combination is designed to treat asthma and chronic obstructive pulmonary disease (COPD) and works by reducing inflammation in the airways with budesonide, while formoterol relaxes the muscles around the airways, offering patients a more affordable alternative.
Which leading companies are dominating the budesonide inhaler market landscape?
Major companies operating in the budesonide inhaler market are AstraZeneca plc, GSK plc, Takeda Pharmaceutical Company Limited, Viatris Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Sandoz International GmbH, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Synmosa Biopharma Corporation, Chiesi Farmaceutici S.p.A., Aurobindo Pharma Limited, Cipla Limited, Hikma Pharmaceuticals PLC, Lupin Limited, Orion Corporation, Nephron Pharmaceuticals Corporation, Curia Global Inc., Kindeva Drug Delivery L.P., Minakem SAS, Axplora Group GmbH, Cosmo Pharmaceuticals N.V., Manus Aktteva Biopharma LLP, Tovec Pharma Pvt. Ltd., Nutra Respiro Healthcare Pvt. Ltd.
Which geographic areas are expected to offer the highest growth opportunities in thebudesonide inhaler market?
North America was the largest region in the budesonide inhaler market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the budesonide inhaler market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Budesonide Inhaler Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/customise?id=24181&type=smp
Need Customized Data On Budesonide Inhaler Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24181&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
